HRP20120069T1 - Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii - Google Patents

Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii Download PDF

Info

Publication number
HRP20120069T1
HRP20120069T1 HR20120069T HRP20120069T HRP20120069T1 HR P20120069 T1 HRP20120069 T1 HR P20120069T1 HR 20120069 T HR20120069 T HR 20120069T HR P20120069 T HRP20120069 T HR P20120069T HR P20120069 T1 HRP20120069 T1 HR P20120069T1
Authority
HR
Croatia
Prior art keywords
chloro
group
phenyl
propoxy
dimethylamino
Prior art date
Application number
HR20120069T
Other languages
English (en)
Inventor
Altenburger Jean-Michel
Fossey Val�rie
Galtier Daniel
Petit Fr�d�ric
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20120069T1 publication Critical patent/HRP20120069T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Spoj, naznačen time što je spoj formule (I) u kojoj: X i Y, međusobno neovisno, predstavljaju atom dušika ili lanac -CR4-, u kojem R4 predstavlja atom vodika ili (C1-C4)alkil ili alkoksi skupina; A predstavlja arilnu ili heteroarilnu skupinu, gdje su navedene arilna ili heteroarilna skupina izborno supstituirane s jednom ili više skupina, koje se bira između atoma halogena, hidroksi skupine, (C1-C4)alkila, (C3-C5)cikloalkila, (C1-C4)alkoksi, izborno supstituiranog s (C1-C4)alkoksi, halogenalkilnom ili halogenalkoksi skupinom, ili nitrilnu skupinu; W predstavlja atom halogena ili halogenalkilnu skupinu; Z predstavlja (C1-C4)alkilensku skupinu, izborno supstituiranu s jednom ili više skupina, koje se bira između atoma halogena i (C1-C4)alkilne, hidroksi i (C1-C4)alkoksi skupine; B predstavlja skupinu -NR4R5, u kojoj R4 i R5, međusobno neovisno, predstavljaju (C1-C4)alkilnu skupinu; R1 i R2 predstavljaju: • bilo slučaj kada R1 predstavlja atom vodika, a R2 predstavlja (C1-C4)alkilnu skupinu, • ili R1 i R2, zajedno s atomom ugljika na kojeg su vezani, tvore monociklički ili policiklički sustav, kojeg se bira između: (C3-C8)cikloalkilne skupine, premoštena bicikličke skupine ili premoštene tetracikličke skupine, gdje navedeni sustav može biti supstituiran s jednom ili više hidroksi skupina; R3 predstavlja: • bilo skupinu C(O)R5, gdje R5 predstavlja (C1-C4)alkoksi skupinu, izborno supstituiranu s (C1-C4)alkoksi skupinom ili skupinom NR6R7, gdje R6 i R7, međusobno neovisno, predstavljaju atom vodika ili (C1-C4)alkilnu, (C3-C5)cikloalkilnu, (C1-C4)alkilsulfonilnu ili halogenalkilnu skupinu, • ili skupinu CH2XR8, u kojoj:- X predstavlja atom kisika, a R8 predstavlja atom vodika ili (C1-C4)alkilnu skupinu,- ili X predstavlja skupinu NH, a R8 predstavlja (C1-C4)alkilkarbonilnu, (C1-C4)alkilkarboksilnu ili (C1-C4)alkilsulfonilnu skupinu, • ili nitrilnu skupinu (CN); p predstavlja cijeli broj od 0 ili 1, u obliku baze ili adicijske soli s kiselinom ili bazom, a također i njegovi enantiomeri i dijastereoizomeri, uključujući njihove racemične smjese. Patent sadrži još 14 patentnih zahtjeva.

Claims (15)

1. Spoj, naznačen time što je spoj formule (I) [image] u kojoj: X i Y, međusobno neovisno, predstavljaju atom dušika ili lanac -CR4-, u kojem R4 predstavlja atom vodika ili (C1-C4)alkil ili alkoksi skupina; A predstavlja arilnu ili heteroarilnu skupinu, gdje su navedene arilna ili heteroarilna skupina izborno supstituirane s jednom ili više skupina, koje se bira između atoma halogena, hidroksi skupine, (C1-C4)alkila, (C3-C5)cikloalkila, (C1-C4)alkoksi, izborno supstituiranog s (C1-C4)alkoksi, halogenalkilnom ili halogenalkoksi skupinom, ili nitrilnu skupinu; W predstavlja atom halogena ili halogenalkilnu skupinu; Z predstavlja (C1-C4)alkilensku skupinu, izborno supstituiranu s jednom ili više skupina, koje se bira između atoma halogena i (C1-C4)alkilne, hidroksi i (C1-C4)alkoksi skupine; B predstavlja skupinu -NR4R5, u kojoj R4 i R5, međusobno neovisno, predstavljaju (C1-C4)alkilnu skupinu; R1 i R2 predstavljaju: • bilo slučaj kada R1 predstavlja atom vodika, a R2 predstavlja (C1-C4)alkilnu skupinu, • ili R1 i R2, zajedno s atomom ugljika na kojeg su vezani, tvore monociklički ili policiklički sustav, kojeg se bira između: (C3-C8)cikloalkilne skupine, premoštena bicikličke skupine ili premoštene tetracikličke skupine, gdje navedeni sustav može biti supstituiran s jednom ili više hidroksi skupina; R3 predstavlja: • bilo skupinu C(O)R5, gdje R5 predstavlja (C1-C4)alkoksi skupinu, izborno supstituiranu s (C1-C4)alkoksi skupinom ili skupinom NR6R7, gdje R6 i R7, međusobno neovisno, predstavljaju atom vodika ili (C1-C4)alkilnu, (C3-C5)cikloalkilnu, (C1-C4)alkilsulfonilnu ili halogenalkilnu skupinu, • ili skupinu CH2XR8, u kojoj: – X predstavlja atom kisika, a R8 predstavlja atom vodika ili (C1-C4)alkilnu skupinu, – ili X predstavlja skupinu NH, a R8 predstavlja (C1-C4)alkilkarbonilnu, (C1-C4)alkilkarboksilnu ili (C1-C4)alkilsulfonilnu skupinu, • ili nitrilnu skupinu (CN); p predstavlja cijeli broj od 0 ili 1, u obliku baze ili adicijske soli s kiselinom ili bazom, a također i njegovi enantiomeri i dijastereoizomeri, uključujući njihove racemične smjese.
2. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što X i Y, međusobno neovisno, predstavljaju atom dušika ili lanac -CR4-, u kojem R4 predstavlja atom vodika; A predstavlja arilnu ili heteroarilnu skupinu, gdje su navedene arilna i heteroarilna skupina izborno supstituirane s jednom ili više skupina, koje se bira između atoma halogena, hidroksi skupine, (C1-C4)alkila, (C3-C5)cikloalkila, (C1-C4)alkoksi, izborno supstituiranog s (C1-C4)alkoksi, halogenalkilnom ili halogenalkoksi skupinom; W predstavlja atom halogena; Z predstavlja (C1-C4)alkilensku skupinu; B predstavlja skupinu -NR4R5, u kojoj R4 i R5, međusobno neovisno, predstavljaju (C1-C4)alkilnu skupinu, R1 i R2 predstavljaju: • bilo slučaj kada R1 predstavlja atom vodika, a R2 predstavlja (C1-C4)alkilnu skupinu, • ili R1 i R2, zajedno s atomom ugljika na kojeg su vezani, tvore monociklički ili policiklički sustav, kojeg se bira između (C3-C8)cikloalkilne skupine ili premoštene tetracikličke skupine, gdje navedeni sustav može biti supstituiran s jednom ili više hidroksi skupina; R3 predstavlja: • bilo skupinu C(O)R5, gdje R5 predstavlja (C1-C4)alkoksi skupinu, izborno supstituiranu s (C1-C4)alkoksi skupinom ili skupinom NR6R7, gdje R6 i R7, međusobno neovisno, predstavljaju atom vodika ili (C1-C4)alkilnu, (C3-C5)cikloalkilnu, (C1-C4)alkilsulfonilnu ili halogenalkilnu skupinu, • ili skupinu CH2XR8, gdje X predstavlja atom kisika, a R8 predstavlja atom vodika ili (C1-C4)alkilnu skupinu, • ili nitrilnu skupinu (CN); p predstavlja cijeli broj od 0 ili 1, u obliku baze ili adicijske soli s kiselinom ili bazom, a također i njegovi enantiomeri i dijastereoizomeri, uključujući njihove racemične smjese.
3. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što: X predstavlja atom dušika, a Y predstavlja atom dušika ili lanac -CR4-, u kojem R4 predstavlja atom vodika; A predstavlja arilnu skupinu, izborno supstituiranu s jednom ili više skupina, koje se bira između atoma halogena, (C1-C4)alkila, (C3-C5)cikloalkila, (C1-C4)alkoksi ili halogenalkoksi, ili predstavlja heteroarilnu skupinu, izborno supstituiranu s jednom ili više skupina, koje se bira između atoma halogena ili (C1-C4)alkila; W predstavlja atom halogena; Z predstavlja (C1-C4)alkilensku skupinu; B predstavlja skupinu -NR4R5, u kojoj R4 i R5, međusobno neovisno, predstavljaju (C1-C4)alkilnu skupinu, R1 i R2 predstavljaju: • bilo slučaj kada R1 predstavlja atom vodika, a R2 predstavlja (C1-C4)alkilnu skupinu, • ili R1 i R2, zajedno s atomom ugljika na kojeg su vezani, tvore (C3-C8)cikloalkilnu skupinu, izborno supstituiranu s jednom ili više hidroksi skupina ili adamantilnu skupinu; R3 predstavlja: • bilo skupinu C(O)R5, gdje R5 predstavlja (C1-C4)alkoksi skupinu, izborno supstituiranu s (C1-C4)alkoksi skupinom ili skupinom NR6R7, gdje R6 predstavlja atom vodika, a R7 predstavlja atom vodika ili (C1-C4)alkilnu, (C3-C5)cikloalkilnu, (C1-C4)alkilsulfonilnu ili halogenalkilnu skupinu, • ili skupinu -CH2XR8, gdje X predstavlja atom kisika, a R8 predstavlja atom vodika ili (C1-C4)alkilnu skupinu, p predstavlja cijeli broj 0 ili 1, u obliku baze ili adicijske soli s kiselinom ili bazom, a također i njegovi enantiomeri i dijastereoizomeri, uključujući njihove racemične smjese.
4. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što je hidroklorid.
5. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih spojeva: metil-1-{[(3,5-diklor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(4-hidroksi-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(5-hidroksi-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-{[(3-klor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-metil-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-1-{[(6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-[5-(2-metoksietoksi)-2-metilfenil]piridin-2-il)karbonil]amino}cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(5-ciklopropil-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(5-izopropoksi-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klor-5-propoksifenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(5-etoksi-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(6-metil-1,3-benzodioksol-5-il)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-{[(3-klor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-fluoro-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-1-{[(2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-3,5-dimetil-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(3-hidroksi-2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-{[(2-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-2'-metil-3,3'-bipiridin-6-il)karbonil]amino}cikloheksankarboksilata; metil-1-{[(6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-[5-(difluorometoksi)-2-metilfenil]piridin-2-il)karbonil]amino}cikloheksankarboksilata; metil-1-{[(6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-[2-(difluorometil)-5-metilfenil]piridin-2-il)karbonil]amino}cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(3,5-dimetil-1H-pirazol-1-il)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}5-(3,5-dietil-1H-pirazol-1-il)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2,4-dimetilfenil)pirazin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klor-5-etoksifenil)pirazin-2-il]karbonil}amino)cikloheksankarboksilata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klor-5-metilfenil)piridin-2-il]karbonil}amino)-4-metilpentanoata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2,4-dimetilfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klor-5-etoksifenil)pirazin-2-il]karbonil}amino)-4,4-dimetilpentanoata; metil-(3S)-3-{[(3-klor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-fluoro-2,3'-bipiridin-6'-il)karbonil]amino}-4,4-dimetilpentanoata; metil-2-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klorfenil)piridin-2-il]karbonil}amino)adamantane-2-karboksilata; 2-metoksietil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; etil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; izopropil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klorfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; N-[(1S)-1-(2-amino-2-oksoetil)-2,2-dimetilpropil]-6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-{(1S)-2,2-dimetil-1-[2-(metilamino)-2-oksoetil]propil}-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-2,2-dimetil-1-{2-[(metilsulfonil)amino]-2-oksoetil}propil]-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-1-{2-[(1,1,1-trifluoroetil)amino]-2-oksoetil}-2,2-dimetilpropil]-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-1-{2-[ciklopropil(metil)amino]-2-oksoetil}-2,2-dimetilpropil]-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-1-(2-hidroksietil)-2,2-dimetilpropil]-5-(2-metil-fenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-1(2-metoksietil)-2,2-dimetilpropil]-5-(2-metil-fenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(2S)-1-cyano-3,3-dimetilbutan-2-il]-5-(2-metilfenil)piridin-2-karboksamida; metil-cis-1-{[(3,5-diklor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-2,3'-bipiridin-6'-il)karbonil]amino}-4-hidroksicikloheksankarboksilata; metil-cis-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2,4-dimetilfenil)piridin-2-il]karbonil}amino)-4-hidroksicikloheksankarboksilata; metil-cis-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4-hidroksicikloheksankarboksilata; metil-cis-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(5-etoksi-2-metilfenil)piridin-2-il]karbonil}amino)-4-hidroksicikloheksankarboksilata; metil-cis-1-{[(3-klor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-metil-2,3'-bipiridin-6'-il)karbonil]amino}-4-hidroksicikloheksankarboksilata.
6. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih spojeva: metil-1-{[(3,5-diklor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)cikloheksankarboksilata; metil-1-{[(3-klor-2'-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-metil-2,3'-bipiridin-6'-il)karbonil]amino}cikloheksankarboksilata; metil-(3S)-3-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-klorfenil)piridin-2-il]karbonil}amino)-4,4-dimetilpentanoata; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-2,2-dimetil-1-{2-[(metilsulfonil)amino]-2-oksoetil}propil]-5-(2-metilfenil)piridin-2-karboksamida; 6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-N-[(1S)-1-(2-hidroksietil)-2,2-dimetilpropil]-5-(2-metil-fenil)piridin-2-karboksamida; metil-cis-1-({[6-{4-klor-3-[3-(dimetilamino)propoksi]fenil}-5-(2-metilfenil)piridin-2-il]karbonil}amino)-4-hidroksicikloheksankarboksilata.
7. Postupak dobivanja spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što spoj formule (II): [image] u kojoj su X, Y, Z, W, A i B definirani kao u patentnom zahtjevu 1, reagira sa spojem formule (III): [image] u kojoj su R1, R2 i R3 definirani kao u patentnom zahtjevu 1.
8. Postupak dobivanja spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što spoj formule (IV): [image] u kojoj su X, Y, Z, W, A i B definirani kao u patentnom zahtjevu 1, reagira sa spojem formule R5H, gdje je R5 definiran kao u patentnom zahtjevu 1.
9. Postupak dobivanja spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što spoj formule (IV): [image] reagira s reducensom.
10. Medikament, naznačen time što sadrži spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili adicijska sol tog spoja s farmaceutski prihvatljivom kiselinom ili bazom, ili alternatively an enantiomer, dijastereoizomer ili racemična smjesa tog spoja.
11. Farmaceutski pripravak, naznačen time što sadrži spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili adicijsku sol tog spoja s farmaceutski prihvatljivom kiselinom ili bazom, enantiomer, dijastereoizomer ili racemičnu smjesu tog spoja, a također i najmanje jednu farmaceutski prihvatljivu pomoćnu tvar.
12. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je navedeni spoj namijenjen pripravi medikamenta za liječenje i/ili sprječavanje kongestivne insuficijencije srca, ishemije srca, infarkta miokarda, hipertrofije i fibroze srca, bolesti i ateroskleroze koronarnih krvnih žila, sistemne i plućne arterijske hipertenzije, portalne hipertenzije, fibroze jetre, postangioplastične restenoze, akutne i kronične insuficijencije bubrega uzrokovane dijabetesom i/ili hipertenzijom, dijabetesa, upale, fibroza i aneurizama, poremećaja središnjeg živčanog sustava, uključujući neurodegenerativne bolesti, inzulte, stres, anksioznost, agresivnost, depresiju, shizofreniju, ili poremećaje spavanja i rak, ili bolesti dišnog sustva, te astmu.
13. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je navedeni spoj namijenjen pripravi medikamenta za liječenje i/ili sprječavanje akutne i kronične insuficijencije bubrega uzrokovane dijabetesom.
14. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je navedeni spoj namijenjen pripravi medikamenta za liječenje i/ili sprječavanje dijabetesa.
15. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je navedeni spoj namijenjen pripravi medikamenta za liječenje i/ili sprječavanje povraćanja.
HR20120069T 2008-02-07 2012-01-23 Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii HRP20120069T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800651A FR2927330B1 (fr) 2008-02-07 2008-02-07 Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
PCT/FR2009/000128 WO2009115665A1 (fr) 2008-02-07 2009-02-05 Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii

Publications (1)

Publication Number Publication Date
HRP20120069T1 true HRP20120069T1 (hr) 2012-02-29

Family

ID=39434382

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120069T HRP20120069T1 (hr) 2008-02-07 2012-01-23 Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii

Country Status (22)

Country Link
US (2) US8466292B2 (hr)
EP (1) EP2238110B1 (hr)
JP (1) JP2011511046A (hr)
KR (1) KR20100116183A (hr)
CN (1) CN101981008B (hr)
AR (1) AR070573A1 (hr)
AT (1) ATE530527T1 (hr)
AU (1) AU2009227091B2 (hr)
BR (1) BRPI0907719A2 (hr)
CA (1) CA2715096A1 (hr)
CY (1) CY1112670T1 (hr)
DK (1) DK2238110T3 (hr)
ES (1) ES2375339T3 (hr)
FR (1) FR2927330B1 (hr)
HR (1) HRP20120069T1 (hr)
IL (1) IL207356A0 (hr)
MX (1) MX2010008713A (hr)
PL (1) PL2238110T3 (hr)
PT (1) PT2238110E (hr)
RU (1) RU2497808C2 (hr)
SI (1) SI2238110T1 (hr)
WO (1) WO2009115665A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
EA201590693A1 (ru) 2012-10-05 2015-08-31 Ригель Фармасьютикалс, Инк. Ингибиторы gdf-8
CN106029663B (zh) 2013-12-24 2018-06-01 百时美施贵宝公司 作为抗癌剂的新颖三环化合物
WO2016138472A1 (en) 2015-02-27 2016-09-01 Calcimedica, Inc. Pancreatitis treatment
ES2815683T3 (es) 2015-05-11 2021-03-30 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
EP3328861A1 (en) 2015-07-28 2018-06-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017027400A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
BR112018010410A8 (pt) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0104332D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
CA2767153A1 (en) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
JP2006519258A (ja) * 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
FR2856684B1 (fr) * 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2904827B1 (fr) * 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii

Also Published As

Publication number Publication date
CA2715096A1 (fr) 2009-09-24
US20130252974A1 (en) 2013-09-26
EP2238110A1 (fr) 2010-10-13
RU2497808C2 (ru) 2013-11-10
CN101981008B (zh) 2013-07-31
FR2927330A1 (fr) 2009-08-14
PL2238110T3 (pl) 2012-03-30
CY1112670T1 (el) 2016-02-10
IL207356A0 (en) 2010-12-30
MX2010008713A (es) 2010-09-09
WO2009115665A1 (fr) 2009-09-24
AR070573A1 (es) 2010-04-21
BRPI0907719A2 (pt) 2015-07-14
SI2238110T1 (sl) 2012-02-29
ATE530527T1 (de) 2011-11-15
FR2927330B1 (fr) 2010-02-19
CN101981008A (zh) 2011-02-23
AU2009227091A1 (en) 2009-09-24
EP2238110B1 (fr) 2011-10-26
PT2238110E (pt) 2012-01-02
AU2009227091B2 (en) 2013-05-23
KR20100116183A (ko) 2010-10-29
JP2011511046A (ja) 2011-04-07
US8466292B2 (en) 2013-06-18
ES2375339T3 (es) 2012-02-29
DK2238110T3 (da) 2012-02-20
US20110009426A1 (en) 2011-01-13
RU2010137115A (ru) 2012-03-20
US8653276B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
HRP20120069T1 (hr) Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii
ES2549087T3 (es) Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
JP4693787B2 (ja) Ｃｂ１拮抗活性を有する１，３，５−三置換４，５−ジヒドロ−１ｈ−ピラゾール誘導体
ES2280599T3 (es) Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1.
ES2197167T3 (es) Imidazoles trisustituidos con multiples propiedades terapeuticas.
TW502019B (en) Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
ES2315851T3 (es) Derivados de imidazolina que tienen actividad antagonista cb1.
HRP20120559T1 (hr) Derivati bisaril piridinkarboksamida njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
JP4177435B2 (ja) 治療薬
BR112017009701B1 (pt) Composto e métodos de preparação de compostos
JP2007533621A (ja) カンナビノイド受容体調整剤としてのチアゾール誘導体
JP2011528372A (ja) α７ニコチン性アセチルコリンレセプターインヒビター
BRPI0706610A2 (pt) moduladores de receptores alfa 7 nicotìnico acetilcolina e usos terapêuticos destes
UA77440C2 (en) 1h-imidazole derivatives as potent cannabinoid-cb1 receptor agonists, partial agonists or antagonists, methods of their preparation (variants), intermediates, pharmaceutical composition and method for preparation thereof
JP2010516635A5 (hr)
JP2007519754A5 (hr)
RU2430923C2 (ru) Тиазолилдигидрохиназолины
ATE458483T1 (de) Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
CN102548963A (zh) 新颖的作为MDM2-p53相互作用抑制剂的N经取代的吡咯烷类化合物
EA016948B1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
JP2008508351A5 (hr)
NL1025933C2 (nl) 4-Fenyl-piperidineverbindingen en de toepassing ervan als modulatoren van opioïde receptoren.